Edge Therapeutics, Inc. (NASDAQ:EDGE) insider Brian A. Leuthner sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $10.53, for a total transaction of $78,975.00. Following the sale, the insider now directly owns 125,236 shares in the company, valued at $1,318,735.08. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Edge Therapeutics, Inc. (EDGE) traded up 0.77% on Friday, hitting $10.44. 20,971 shares of the company were exchanged. The company’s market capitalization is $321.85 million. The stock has a 50 day moving average of $10.30 and a 200 day moving average of $9.79. Edge Therapeutics, Inc. has a 52 week low of $7.30 and a 52 week high of $13.50.

Edge Therapeutics (NASDAQ:EDGE) last announced its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported ($0.44) EPS for the quarter, hitting analysts’ consensus estimates of ($0.44). Analysts predict that Edge Therapeutics, Inc. will post ($1.87) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/08/04/edge-therapeutics-inc-edge-insider-brian-a-leuthner-sells-7500-shares-of-stock.html.

EDGE has been the topic of a number of research reports. BidaskClub raised shares of Edge Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. Zacks Investment Research downgraded shares of Edge Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday.

A number of hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. raised its stake in shares of Edge Therapeutics by 6.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 74,747 shares of the biotechnology company’s stock worth $681,000 after buying an additional 4,788 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Edge Therapeutics during the first quarter valued at approximately $297,000. Geode Capital Management LLC raised its position in shares of Edge Therapeutics by 5.0% in the first quarter. Geode Capital Management LLC now owns 172,646 shares of the biotechnology company’s stock valued at $1,572,000 after buying an additional 8,181 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Edge Therapeutics by 2.9% in the first quarter. Vanguard Group Inc. now owns 700,003 shares of the biotechnology company’s stock valued at $6,377,000 after buying an additional 19,973 shares in the last quarter. Finally, Spark Investment Management LLC purchased a new position in shares of Edge Therapeutics during the first quarter valued at approximately $157,000. 48.72% of the stock is owned by institutional investors.

About Edge Therapeutics

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Stock Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related stocks with our FREE daily email newsletter.